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Abstract
Objectives. To investigate whether anti-CCP2-positive at-risk individuals with musculoskeletal (MSK) symptoms
but without clinical synovitis (CCP2þ at-risk) develop US subclinical synovitis before inflammatory arthritis and if US
subclinical synovitis can be predicted.
Methods. First, US scans of CCP2þ at-risk individuals who developed inflammatory arthritis (‘progressors’) were
reviewed for subclinical synovitis prior to inflammatory arthritis development. Patients in whom the pre-progression
US scan was negative but the scan was conducted >6 months before progression were excluded. Subsequently,
regression analyses were performed to identify predictors of US synovitis in CCP2þ at-risk individuals without base-
line US abnormalities who had one or more longitudinal US scan and a complete dataset.
Results. US subclinical synovitis was detected in one or more scan in 75 of 97 progressors (77.3%) fmedian time
to inflammatory arthritis development from first evidence of US synovitis 26.5 weeks [interquartile range (IQR) 7–60]g,
in whom one or more scan was available, excluding those with a negative scan >6 months from inflammatory arthritis
development (n¼ 38). In 220 CCP2þ at-risk individuals with normal baseline US scans, who had one or more longitu-
dinal US scan and a complete dataset, US synovitis was detected in 69/220 (31.4%) [median time to first developing
US synovitis 56.4 weeks (IQR 33.0–112.0)]. In the multivariable analysis, only anti-CCP3 antibodies were predictive for
the development of US synovitis [odds ratio 4.75 (95% CI 1.97, 11.46); P< 0.01].
Conclusions. In anti-CCP2þ at-risk individuals, a stage of subclinical synovitis usually precedes the development
of inflammatory arthritis. Anti-CCP2þ/CCP3þ individuals without clinical or US subclinical synovitis may represent
the optimal window of opportunity for intervention to prevent joint disease.
Key words: ACPA, ultrasound, at-risk, third-generation anti-CCP antibodies, anti-CCP3, subclinical synovitis,
prediction, rheumatoid arthritis, inflammatory arthritis
Rheumatology key messages
. The majority of anti-CCP2-positive at-risk individuals go through a stage of subclinical synovitis before the
development of inflammatory arthritis.
. CCP2-positive at-risk individuals can be identified prior to any joint involvement by the presence of anti-CCP3
antibodies.
. This may represent the optimal ‘window of opportunity’ for intervention to prevent joint disease.
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The concept of early RA has recently evolved. It is now
considered a ‘disease continuum’ rather than a fixed
phenotype, in which individuals with risk factors pro-
gress through different stages before the development
of clinical arthritis [1–3].
In 2012, the EULAR Standing Committee on
Investigative Rheumatology defined six categories along
the preclinical ‘RA continuum’: genetic (phase A) and envir-
onmental (phase B) risk factors for RA, RA-related system-
ic autoimmunity (phase C), musculoskeletal (MSK)
symptoms without clinical arthritis (phase D), undifferenti-
ated arthritis (phase E) and RA (phase F) [4] (Fig. 1).
Recently, several studies have highlighted the pres-
ence of another important population along this ‘con-
tinuum’, which sits between phases D and E. This is
represented by at-risk individuals (i.e. those with sys-
temic autoimmunity and MSK symptoms but without
clinical arthritis) who have subclinical joint inflammation
on US or MRI [5–7]. These studies have demonstrated
that high-resolution imaging is able to detect subclinical
joint inflammation in at-risk individuals before clinical
synovitis occurs. Indeed, the detection of baseline sub-
clinical joint inflammation and/or joint damage on US
has been demonstrated to greatly increase the risk of
progression to inflammatory arthritis in at-risk individuals
[8–11]. When US power Doppler (PD) is detectable in
four or more joints, the future development of RA is al-
most certain, suggesting this occurs at a late stage in
the ‘continuum’ [12]. An additional and important aspect
that has emerged is that the occurrence of MSK symp-
toms seems to precede, in most at-risk individuals, the
development of subclinical joint inflammation and/or
joint damage on US [13, 14]. Symptoms in the absence
of clinical or subclinical inflammation may represent the
critical time point for preventive treatments, particularly
for joint disease.
The identification of those individuals who are at immi-
nent risk, ideally in the window before the occurrence of
any joint involvement (i.e. before the ‘second hit’ of RA
occurs), is of utmost importance for risk stratification
and consequently for disease prevention. However, this
is challenging to achieve and therefore biomarkers that
can identify those individuals who will develop joint dis-
ease would be of great value.
The aims of this study were 2-fold: to investigate
whether US subclinical synovitis represents a distinct
stage of the ‘continuum’ in second-generation IgG
anti-CCP antibody–positive (CCP2þ) at-risk individu-
als prior to the development of clinical inflammatory
arthritis and to determine in anti-CCP2þ at-risk
individuals with MSK symptoms but before joint in-
volvement (neither clinical nor subclinical synovitis),
clinical and/or serological predictors of US subclinical
synovitis.
Methods
CCP2þ (BioPlex 2200, Bio-Rad Laboratories, Hercules,
CA, USA) at-risk individuals with MSK symptoms, but
without clinical synovitis, taking part in the Leeds CCP
study from June 2008 to March 2020 were included. Full
details of ‘The CCP Study: Coordinated Programme to
Prevent Arthritis – Can We Identify Arthritis at a Pre-
clinical Stage?’ have been previously reported [15, 16].
Briefly, in this national study, individuals 18 years of
age with new MSK symptoms, who test positive for
anti-CCP antibodies, are invited to a dedicated research
clinic at Chapel Allerton Hospital (Leeds, UK) as part of
an observational study. Anti-CCP2 antibody is the most
used test to detect ACPA in many places, including the
UK. Different from some other at-risk cohorts currently
being followed internationally [17, 18], all subjects in the
Leeds CCP study are anti-CCP2þ.
FIG. 1 Categories along the RA ‘continuum’ defined by the EULAR Standing Committee on Investigative Rheumatology
UA: undifferentiated arthritis.
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In anti-CCP2þ at-risk individuals, the following data
were collected at baseline: age, gender, early morning
stiffness (EMS) duration, tenderness in the small joints
of the hands on physical examination, anti-CCP2 level,
third-generation IgG anti-CCP antibody (anti-CCP3) level
(QUANTA Lite CCP3, Inova Diagnostic, San Diego, CA,
USA) and IgM RF status (BNII nephelometry before
February 2010, AdviaXPT turbidometry after February
2010; Siemens, Munich, Germany).
The anti-CCP2 and anti-CCP3 test positivity threshold
was set according to the manufacturer’s cut-offs
(>2.99 IU/ml and 20 units, respectively). The anti-CCP2
level was considered low or high when it was <3 or 3
times the positivity threshold, respectively, according to
the ACR/EULAR 2010 criteria [19].
A full US protocol was performed as part of the Leeds
CCP study. The following joints were scanned: elbows,
wrists, first–fifth MCP joints, first–fifth PIP joints, knees,
ankles and first–fifth MTP joints. The first MTP joint was
not included in the analyses, as US abnormalities have
been frequently detected at this level in other non-
inflammatory joint diseases, such as OA, as well as in
asymptomatic healthy subjects [20, 21]. US synovitis
(synovial hypertrophy 1 and PD signal 1) and bone
erosions were identified according to the EULAR/
OMERACT and OMERACT definitions, respectively [22,
23]. Three different US machines were used during the
study: an ATL HDI 5000 (Philips US, Cambridge, MA,
USA), employing 5–12 MHz and 8–15 MHz transducers,
and an S7 and Logiq E9 (GE Healthcare, Chicago, IL,
USA), both employing a 6–15 MHz transducer. PD was
set as follows: pulse repetition frequency (PRF) 700–
1000 Hz, Doppler frequency 6 MHz for the ATL HDI 5000
and 10 MHz for the S7 and Logic E9. Sensitivity analy-
ses between the first two US machines (ATL HDI 5000
and S7) were performed due to the change in the US
machine during the study [8]. Given the positive results
of this analyses and the fact that the S7 was replaced
with another GE machine (Logiq E9), the same analyses
were not repeated for the third US machine used.
This study consisted of two parts. In the first part (US
subclinical synovitis prior to the development of inflam-
matory arthritis), among at-risk individuals who pro-
gressed to inflammatory arthritis, the prevalence and
distribution of subclinical synovitis was evaluated in the
US scans conducted prior to inflammatory arthritis de-
velopment. Patients in whom the pre-progression US
scan was negative, but the scan was conducted
>6 months before progression, were excluded. The rea-
son for this choice was based on the fact that the ma-
jority of anti-CCP2þ individuals with US synovitis who
progress to inflammatory arthritis do so within a short-
term follow-up (i.e. median 7.9–9.9 months) [15, 16].
Therefore, individuals with a negative US scan several
months before progression may well have subsequently
developed an undetected subclinical synovitis. In the se-
cond part of the study (predicting the development of
US subclinical synovitis), we selected only anti-CCP2þ
individuals without US abnormalities at baseline (i.e.
neither US synovitis nor bone erosions) who had one or
more longitudinal US scan and in whom a complete
dataset was available. In these patients, we investigated
predictors of subclinical synovitis on longitudinal scans.
This study was approved by the NHS Health
Research Authority National Research Ethics Service
Committee Yorkshire & the Humber–Leeds West. All
individuals participating in the study provided full written
informed consent.
Statistical analysis
Descriptive statistics were used to describe the main
characteristics of the study population and reported as
absolute frequencies with the corresponding percentage
for categorical variables, mean (S.D.) for continuous vari-
ables with a normal distribution and median with inter-
quartile range (IQR) for non-normally distributed
continuous variables. The chi-squared test was used for
comparing categorical variables. The Mann–Whitney U
test was used to compare continuous variables. A uni-
variable analysis was performed to define the predictive
value of age, gender, anti-CCP2 antibodies (high/low),
anti-CCP3 antibodies (positive/negative), RF (positive/
negative), EMS >30 min and tenderness in the small
joints of the hands on physical examination for the de-
velopment of US subclinical synovitis at follow-up. The
multivariable regression analysis was adjusted for those
parameters that were significant in the univariable ana-
lysis. In addition, we performed three different multivari-
able models excluding either anti-CCP2 (high level),
anti-CCP3 or RF, to rule out the potential influence of
the collinearity between these variables on the multivari-
able analysis results. The collinearity between anti-
CCP2, anti-CCP3 and RF was also explored using
Cramér’s V. A coefficient >0.60 was considered to be
indicative of collinearity. Kaplan–Meier analysis and log-
rank tests were performed to evaluate the US subclinical
synovitis-free survival time for anti-CCP3 antibodies and
RF. Statistical analyses were performed using SPSS ver-
sion 25.0 for Windows (IBM, Armonk, NY, USA). The
level of significance was set at 5%.
Results
US subclinical synovitis prior to the development of
inflammatory arthritis
A total of 155/620 (25.0%) anti-CCP2þ at-risk individuals
progressed to inflammatory arthritis [median time to de-
velop inflammatory arthritis from the baseline visit:
51 weeks (IQR 24–107.2)]. At least one US scan per-
formed prior to the development of clinical arthritis was
available in 135/155 progressors (87.1%). Thirty-eight
individuals in whom the most recent scan before progres-
sion was negative and where this scan was >6 months
before progression were excluded. US subclinical syno-
vitis was detected in one or more scan in 75 of the
remaining 97 individuals (77.3%) [median time to inflam-
matory arthritis development from first developing US
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synovitis: 26.5 weeks (IQR 7.0–60.0); median number of
joints with US synovitis: 2.0 (IQR 1.0–3.0)].
The demographic and clinical characteristics of pro-
gressors with one or more US scan available is reported
in Table 1.
US subclinical synovitis was detected in the follow-
ing anatomical areas: wrists in 45/75 (60.0%) CCP2þ
individuals, MCP joints in 30/75 (40.0%), MTP joints in
22/75 (29.3%), PIP joints in 17/75 (22.7%), knees in 6/
75 (8.0%), elbows in 1/75 (1.3%) and ankles in 1/75
(1.3%).
Predicting the development of US subclinical
synovitis
A total of 220 CCP2þ individuals with a normal baseline
US scan (i.e. no US synovitis or bone erosions) who had
one or more longitudinal US scan and in whom a com-
plete dataset was available were included in this ana-
lysis. The clinical and demographic characteristics of
individuals included are reported in Table 2.
In 220 CCP2þ at-risk individuals with normal baseline
US scans who had one or more longitudinal US scan







matory arthritis (n 5 75)






analysis* (n 5 38)
Age, years, mean (S.D.) 53.9 (12.8) 56.3 (12.8) 50.0 (10.5) 51.5 (12.4)
Female, n (%) 102 (75.5) 54 (72.0) 15 (68.2) 33 (86.8)
Tenderness in the hands, n (%) 62 (45.9) 38 (50.7) 8 (36.4) 16 (42.1)
EMS, minutes, median (IQR) 15 (0–60) 15 (0–42.5) 37.5 (15–60) 10 (0–30)
Anti-CCP2 antibodies,
n (%)
Low 16 (11.9) 11 (14.7) 1 (4.5) 4 (10.5)
High 119 (88.1) 64 (85.3) 21 (95.5) 34 (89.5)
Anti-CCP3 antibodies,
n (%)
Not available 11 (8.1) 7 (9.3) 0 (0.0) 4 (10.5)
Negative 11 (8.1) 6 (8.0) 3 (13.6) 2 (5.3)
Positive 113 (83.8) 62 (82.7) 19 (86.4) 32 (84.2)
RF, n (%) Negative 49 (36.3) 24 (32.0) 8 (36.4) 17 (44.7)
Positive 86 (63.7) 51 (68.0) 14 (63.6) 21 (55.3)
Only anti-CCP2þ at-risk individuals who progressed to inflammatory arthritis and had one or more US scan prior to inflam-
matory arthritis development are included. *Individuals in whom the most recent scan before progression was negative and
where this scan was >6 months before progression.



















Age, years, mean (S.D.) 48.9 (12.4) 53.0 (10.8) 53.2 (9.6) 52.3 (10.9) 24.9 (12.6)
Female, n (%) 164 (74.5) 49 (71.0) 20 (71.4) 33 (67.3) 115 (76.2)
Tenderness in the hands, n (%) 71 (32.3) 20 (28.2) 8 (28.6) 12 (24.5) 51 (33.8)
EMS, minutes, median (IQR) 5 (0–30) 10 (0–30) 30 (2.5–60) 20 (0–60) 0 (0–30)
Anti-CCP2 antibodies,
n (%)
Low 83 (37.7) 19 (27.5) 8 (28.6) 13 (26.5) 64 (42.4)
High 137 (62.3) 50 (72.5) 20 (71.4) 36 (73.5) 87 (57.6)
Anti-CCP3 antibodies,
n (%)
Negative 109 (49.5) 17 (24.6) 7 (25.0) 11 (22.4) 59 (39.1)
Positive 111 (50.5) 52 (75.4) 21 (75.0) 38 (77.6) 92 (60.9)
RF, n (%) Negative 161 (73.2) 39 (56.5) 16 (57.1) 28 (57.1) 122 (80.8)
Positive 59 (26.8) 30 (43.5) 12 (42.9) 21 (42.9) 29 (19.2)
Only anti-CCP2þ at-risk individuals with normal baseline US scan who had one or more longitudinal US scan and in whom
a complete dataset was available are included.
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and a complete dataset, US synovitis was detected in
69/220 (31.4%) [median time to first developing US
synovitis: 56.4 weeks (IQR 33.0–112.0); median number
of US scans: 2.0 (IQR 1.0–3.0); median number of joints
with US synovitis: 2.0 (IQR 1.0–2.0)].
US subclinical synovitis was detected on longitudinal
scans in the following anatomical areas: wrists in 44/69
(63.8%) CCP2þ individuals, MCP joints in 30/69 (43.5%),
MTP joints in 14/69 (20.3%), knees in 11/69 (15.9%),
PIP joints in 4/69 (5.8%) and elbows in 1/69 (1.4%).
In the univariable analysis, age [OR 1.04 (95% CI
1.02, 1.07), P< 0.01], high level anti-CCP2þ [OR 1.94
(95% CI 1.04, 3.60), P¼0.04], anti-CCP3 antibodies [OR
4.77 (95% CI 2.52, 9.03), P<0.01] and RF [OR 3.24
(95% CI 1.73, 6.05), P<0.01] were predictive for the de-
velopment of US subclinical synovitis on subsequent US
scans. In the multivariable analysis, only anti-CCP3 anti-
bodies remained significantly predictive [OR 4.75 (95%
CI 1.97, 11.46), P<0.01] while borderline results were
observed with age [OR 1.04 (95% CI 1.01, 1.07),
P¼0.01] (Table 3). The predictive value of anti-CCP3 for
US subclinical synovitis development was also observed
when the multivariable analysis was carried out exclud-
ing high-level anti-CCP2 [anti-CCP3 OR 3.60 (95% CI
1.74, 7.44), P<0.01] or RF [anti-CCP3 OR 5.64 (95% CI
2.50, 12.76), P< 0.01] (Supplementary Table S1, avail-
able at Rheumatology online). Interestingly, RF was pre-
dictive for the development of US subclinical synovitis
when anti-CCP3 antibodies were not included in the
multivariable analysis [RF OR 2.61 (95% CI 1.34, 5.08),
P¼0.01]. No significant collinearity between anti-CCP2,
anti-CCP3 and RF was found (V¼ 0.54, 0.28 and 0.52
for anti-CCP2/anti-CCP3, anti-CCP2/RF and anti-CCP3/
RF, respectively).
CCP2þ individuals with positive anti-CCP3 antibodies
show a significantly reduced US subclinical synovitis-free
survival rate compared with individuals with negative anti-
CCP3 antibodies (Fig. 2). At the 1 and 2 year follow-up,
18.9% and 34.2%, respectively, of individuals with dual
CCP2/CCP3 positivity developed subclinical synovitis on
longitudinal scans compared with 6.4% and 10.1% of
CCP2þ individuals with negative anti-CCP3 antibodies
(P<0.01 for both) (Fig. 2a). Similar results were observed
in the subgroup of high-level CCP2þ individuals at the 1
and 2 year follow-up; respectively, 19.4% and 32.7% of
high-level CCP2þ/anti-CCP3þ, but only 2.6% and 10.3%
of high-level CCP2þ individuals with negative anti-CCP3
antibodies developed subclinical synovitis on longitudinal
scans (P¼ 0.01 and P<0.01, respectively) (Fig. 2b). The
impact of RF on subclinical synovitis-free survival rate was
not significant in individuals with positive anti-CCP3 anti-
bodies (Fig. 2c). Conversely, this was notable in individuals
with anti-CCP2þ/RFþ [i.e. 21/59 (35.6%) developed US
subclinical synovitis within 2 years of follow-up] compared
with individuals with positive anti-CCP2þ and negative RF
[i.e. 28/161 (17.4%), P¼ 0.01] (Fig. 2d).
Discussion
The results of the current study show that in CCP2þ at-
risk individuals with MSK symptoms, but without clinical
synovitis, the majority of progressors go through a stage
of US subclinical joint inflammation prior to developing
inflammatory arthritis; this represents a distinct stage of
the ‘RA continuum’. Moreover, this is an important
group to recognize, as it also represents the first transi-
tion of systemic autoimmunity into articular inflamma-
tion, the so-called ‘second hit’ in the pathogenesis of
RA [24] (Fig. 3).
There is increasing evidence from patient-reported
outcomes and the very high predictive value of subclin-
ical synovitis on imaging that the presence of subclinical
synovitis in multiple joints may represent a distinct dis-
ease in its own right [25, 26]. In support of this, serial
US assessments in a cohort of anti-CCP2þ at-risk indi-
viduals suggest that subclinical synovitis occurs directly
before the development of clinical synovitis [27] and the
fact that the majority of anti-CCP2þ individuals with US
synovitis who develop inflammatory arthritis do so within
12 months of follow-up [15, 16]. Of note, in our study,
>60% of progressors had evidence of subclinical syno-
vitis on US scans performed within 6 months prior to in-
flammatory arthritis development.
TABLE 3 Univariable and multivariable regression analyses for the development of US synovitis
Variables Univariable analysis Multivariable analysis
OR (95% CI) P-value OR (95% CI) P-value
Gender (male) 1.30 (0.69, 2.48) 0.42 – –
Age 1.04 (1.02, 1.07) <0.01 1.04 (1.01, 1.07) 0.01
Tenderness in the
hands
1.25 (0.67, 2.32) 0.48 – –
EMS 1.00 (0.99, 1.01) 0.11 – –
Anti-CCP2þ (high
level)
1.94 (1.04, 3.60) 0.04 0.60 (0.26, 1.41) 0.24
Anti-CCP3þ 4.77 (2.52, 9.03) <0.01 4.75 (1.97, 11.46) <0.01
RFþ 3.24 (1.73, 6.05) <0.01 1.46 (0.70, 3.05) 0.31
Significant results are in bold.
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Certainly one might argue that US subclinical inflamma-
tion represents a late feature in the development of in-
flammatory arthritis and, when present, may represent an
inevitable progression to clinical synovitis, especially
when multiple joints are affected; patients who have
progressed this far already have joint inflammation and
therapy may only delay eventual disease progression
rather than truly preventing arthritis [28]. Instead, anti-
CCPþ individuals with MSK symptoms in whom subclin-
ical joint inflammation is not present but imminent may
represent ‘ideal targets’ for therapeutic trials for arthritis
prevention. Halting disease progression in this population
FIG. 3 The ‘disease continuum’ of CCP2þ at-risk individuals
Anti-CCPþ at-risk individuals with MSK symptoms but without any joint involvement (clinical or subclinical) may repre-
sent the critical time point for timing interventions to prevent the onset of joint disease. UA: undifferentiated arthritis.
FIG. 2 Kaplan–Meier analysis shows US subclinical synovitis-free survival time in CCP2þ at-risk individuals
Percentages refer to the individuals who developed US subclinical synovitis at 12 and 24 months follow-up (black
lines). HL: high level.
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would prevent the development of any joint inflammation,
the cardinal feature of RA, and would likely produce bet-
ter outcomes. This is also a valuable population to use
for investigating the immunopathology of RA develop-
ment, as the immunological events that drive the initial
joint involvement in RA (i.e. the ‘second hit’) are not clear.
The position of this population along the early ‘RA con-
tinuum’ is well suited to address this.
The results of the present study show that anti-CCP3
antibodies have a predictive role for the imminent devel-
opment of subclinical synovitis in CCP2þ at-risk individ-
uals. Such predictive value was not replicated with
either high-level anti-CCP2 antibodies or RF, neither of
which were predictive for the development of US syno-
vitis in the multivariable analysis (Table 3). However, it
should be noted that RF was predictive for the develop-
ment of US subclinical synovitis when anti-CCP3 anti-
bodies were not included in the multivariable analysis.
Of note, around a third of high-level anti-CCP2þ/CCP3þ
individuals developed US subclinical synovitis within
2 years of follow-up. On the other hand, only 4/39
(10.3%) high-level anti-CCP2þ/CCP3 individuals devel-
oped US subclinical synovitis on one or more longitudin-
al scan in this time frame (Fig. 2b). Thus the CCP3 result
had a 3-fold effect on the prognostic value of high-level
anti-CCP2 antibodies. As shown in Fig. 2d, a similar
trend was also observed in individuals with double posi-
tive anti-CCP2 and RF in comparison with individuals
with positive anti-CCP2 but negative RF.
Our group has previously demonstrated the predict-
ive role of anti-CCP3 for the development of inflam-
matory arthritis [29]. This is likely to be related to dual
anti-CCP2/CCP3 positivity reflecting an expanded
ACPA repertoire (i.e. different antigenic targets/ACPA
fine specificity being detected) and suggests that in
anti-CCP2þ at-risk individuals, anti-CCP3 antibodies
may be identifying a more advanced stage of auto-
immunity driving the onset of subclinical and later
clinical inflammation [29, 30].
However, progression to inflammatory arthritis in at-
risk individuals with RA-related antibodies and MSK
symptoms is not always inevitable, even in those with
US subclinical joint inflammation. In a recent study,
baseline US synovitis was not associated with the devel-
opment of clinical arthritis at 12 months follow-up in
54% of ACPAþ individuals with arthralgia [31]. The rate
of progression to inflammatory arthritis in at-risk individ-
uals with subclinical synovitis is variable and depends
on several factors, such as the target population (i.e.
asymptomatic first-degree relatives vs individuals with
MSK symptoms and RA-related antibodies), distribution
and number of joints or tendons involved and the type
of US pathological findings detected (e.g. grey-scale
synovitis, PD signal) [32]. In the current study, progres-
sors were found to have a median of 2 joints with US
subclinical synovitis (IQR 1.0–3.0) prior to inflammatory
arthritis development. US subclinical synovitis was main-
ly detected in the wrists, MCP joints and MTP joints
(60.0%, 40.0% and 29.3% of progressors, respectively).
Indeed, further research is needed to establish which
joints, and indeed how many joints, need to be imaged
for optimum predictive accuracy. Most of the US studies
in at-risk cohorts have adopted comprehensive US pro-
tocols that evaluate multiple pathological findings (i.e.
PD signal, grey-scale synovitis and/or bone erosions),
including most or all relevant small joints. In addition,
the interpretation of US-detected synovitis should be
performed in the context of other joint findings. Indeed,
it is well known that inflammation accompanies struc-
tural changes of OA in small and large joints [33].
Our results suggest that anti-CCP2þ/CCP3þ individu-
als without subclinical joint disease are at a critical tran-
sition point in the evolution of RA (i.e. the transition from
autoimmunity to joint inflammation). This transition to the
first detectable phase of joint involvement may represent
the so-called ‘second hit’ in RA pathogenesis and may
be viewed as an additional distinct stage in the ‘RA con-
tinuum’. Moreover, this point may represent a unique
time point for preventing the onset of joint disease.
However, caution is warranted not to dismiss the possi-
bility of participation in prevention trials of those who al-
ready have subclinical joint inflammation.
To our knowledge, this is the first study aimed at
identifying at-risk individuals just before the develop-
ment of subclinical joint involvement. Indeed, this nov-
elty is the main strength of the current study. Moreover,
data are presented from one of the largest prospective
cohorts with the longest follow-up of CCPþ at-risk indi-
viduals. However, all individuals were anti-CCP2þ.
Therefore the results of our study can be interpreted
only in the context of anti-CCP2þ at-risk individuals.
Conclusions
In CCP2þ at-risk individuals with MSK symptoms but
without clinical synovitis, the majority of progressors
go through a stage of US subclinical joint inflammation
prior to the development of inflammatory arthritis, thus
representing a distinct and important stage of the ‘RA
continuum’.
Anti-CCP3 antibodies have a potential role in the iden-
tification of CCP2þ individuals who are about to develop
clinical or subclinical RA-related joint inflammation (i.e.
before the ‘second hit’ in RA pathogenesis occurs). This
may be the ideal population for interventions to prevent
joint disease. This is also a unique population for investi-
gating the drivers of joint involvement in the develop-
ment of RA.
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